Advanced search
Publication Cover
Modern Rheumatology Volume 24, 2014 - Issue 1
Journal homepage
1,203
Views
18
CrossRef citations to date
0
Altmetric
Original Articles

Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study

Norihiro NishimotoOsaka Rheumatology Clinic, Tatsuno-Sinsaibashi-Building 5th Floor, 4-4-10 Minamisenba Chuo-ku, Osaka 542-0081, Japan;Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan;Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, JapanCorrespondence[email protected] [email protected]
,
Koichi AmanoDepartment of Rheumatology/Clinical Immunology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan
,
Yasuhiko HirabayashiDepartment of Rheumatology, Hikarigaoka Spellman Hospital, Sendai, Japan
,
Takahiko HoriuchiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
,
Tomonori IshiiDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Miyagi, Japan
,
Mitsuhiro IwahashiHigashihiroshima Memorial Hospital, Higashihiroshima, Japan
,
Masahiro IwamotoDivision of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
,
Hitoshi KohsakaDepartment of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan
,
Masakazu KondoKondo Clinic of Rheumatology and Orthopaedic Surgery, Fukuoka, Japan
,
Tsukasa MatsubaraMatsubara Mayflower Hospital, Hyogo, Japan
,
Toshihide MimuraDepartment of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan
,
Hisaaki MiyaharaNational Hospital Organization Kyushu Medical Center, Fukuoka, Japan
,
Shuji OhtaDepartment of Rheumatology, Taga General Hospital, Ibaraki, Japan
,
Yukihiko SaekiNational Hospital Organization Osaka-Minami Medical Center, Osaka, Japan
,
Kazuyoshi SaitoThe First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan
,
Hajime SanoDivision of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
,
Kiyoshi TakasugiDohgo Spa Hospital, Ehime, Japan
,
Tsutomu TakeuchiDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan
,
Shigeto TohmaSagamihara National Hospital, National Hospital Organization, Kanagawa, Japan
,
Tomomi TsuruPS Clinic, Fukuoka, Japan
,
Yukitaka UekiSasebo Chuo Hospital, Nagasaki, Japan
,
Jiro YamanaHigashihiroshima Memorial Hospital, Higashihiroshima, Japan
,
Jun HashimotoNational Hospital Organization Osaka-Minami Medical Center, Osaka, Japan
,
Takaji MatsutaniLaboratory of Immune Regulation, Wakayama Medical University, Wakayama, Japan
,
Miho MurakamiDepartment of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan;Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, Japan
&
Nobuhiro TakagiChugai Pharmaceutical Co. Ltd., Tokyo, Japan
 show all
Pages 26-32 | Received 27 Sep 2011, Accepted 15 Apr 2013, Published online: 22 Nov 2013

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Yasuhiko Hirabayashi. (2021) Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis. Modern Rheumatology 31:1, pages 70-79.
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Keiji Maeda. (2019) Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opinion on Drug Delivery 16:6, pages 639-648.
Read now
Atsushi Ogata, Yasuhiro Kato, Shinji Higa & Kazuyuki Yoshizaki. (2019) IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Modern Rheumatology 29:2, pages 258-267.
Read now
Emilio Besada. (2014) Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Preference and Adherence 8, pages 1051-1059.
Read now

Articles from other publishers (14)

Sarah Ringold, Anne C. Dennos, Yukiko Kimura, Timothy Beukelman, Peter Shrader, Thomas A. Phillips, Melanie Kohlheim, Laura E. Schanberg, Rae S. M. Yeung & Daniel B. Horton. (2022) Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care & Research 75:4, pages 715-723.
Crossref
Shunsuke Mori, Akitomo Okada, Tomohiro Koga & Yukitaka Ueki. (2022) Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. PLOS ONE 17:6, pages e0270391.
Crossref
Jacques Morel, Anne Tournadre, Jérémie Sellam, Yoram Bouhnik, Divi Cornec, Valérie Devauchelle-Pensec, Philippe Dieudé, Philippe Goupille, Nicolas Kluger, Estibaliz Lazaro, Benoit Le Goff, Victor de Lédinghen, Thierry Lequerré, Gaëtane Nocturne, Raphaèle Seror, Marie-Elise Truchetet, Frank Verhoeven, Thao Pham & Christophe Richez. (2021) Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 88:4, pages 105221.
Crossref
Carla Bastida, Alwin D.R. Huitema, Merel J. l’Ami, Virginia Ruiz-Esquide, Gerrit Jan Wolbink, Raimon Sanmartí & Dolors Soy. (2020) Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations. European Journal of Clinical Pharmacology 76:10, pages 1417-1425.
Crossref
Jesús Tornero Molina, Alejandro Balsa Criado, Francisco Blanco García, Ricardo Blanco Alonso, Sagrario Bustabad, Jaime Calvo Alen, Héctor Corominas, Antonio Fernández Nebro, Jose Andrés Román Ivorra & Raimon Sanmartí. (2020) Expert recommendations on the interleukin 6 blockade in patients with rheumatoid arthritis. Reumatología Clínica (English Edition) 16:4, pages 272-281.
Crossref
Jesús Tornero Molina, Alejandro Balsa Criado, Francisco Blanco García, Ricardo Blanco Alonso, Sagrario Bustabad, Jaime Calvo Alen, Héctor Corominas, Antonio Fernández Nebro, Jose Andrés Román Ivorra & Raimon Sanmartí. (2020) Recomendaciones de experto sobre el bloqueo de la interleucina 6 en pacientes con artritis reumatoide. Reumatología Clínica 16:4, pages 272-281.
Crossref
Shunsuke Mori & Yukitaka Ueki. (2019) Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. Clinical Rheumatology 38:12, pages 3391-3400.
Crossref
Edwin Jáuregui, Wilson Bautista, Adriana Beltrán, Oscar Felipe, Andrés Fernández, Daniel Fernández, Juan José Jaller, Lina Saldarriaga & Carlos Toro. (2019) Colombian Association of Rheumatology. Consensus on recommendations to decrease and discontinue biological therapy in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Revista Colombiana de Reumatología (English Edition) 26:1, pages 11-23.
Crossref
Edwin Jáuregui, Wilson Bautista, Adriana Beltrán, Oscar Felipe, Andrés Fernández, Daniel Fernández, Juan José Jaller, Lina Saldarriaga & Carlos Toro. (2019) Asociación Colombiana de Reumatología. Consenso sobre recomendaciones para disminución y descontinuación de la terapia biológica en pacientes con artritis reumatoide, espondilitis anquilosante y artritis psoriásica. Revista Colombiana de Reumatología 26:1, pages 11-23.
Crossref
Yuko Kaneko, Masaru Kato, Yoshiya Tanaka, Masayuki Inoo, Hitomi Kobayashi-Haraoka, Koichi Amano, Masayuki Miyata, Yohko Murakawa, Hidekara Yasuoka, Shintaro Hirata, Eiichi Tanaka, Nobuyuki Miyasaka, Hisashi Yamanaka, Kazuhiko Yamamoto & Tsutomu Takeuchi. (2018) Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Annals of the Rheumatic Diseases 77:9, pages 1268-1275.
Crossref
Aleksander Lenert & Petar Lenert. (2016) Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. Clinical Rheumatology 36:1, pages 1-8.
Crossref
T. Martijn Kuijper, Femke B.G. Lamers-Karnebeek, Johannes W.G. Jacobs, Johanna M.W. Hazes & Jolanda J. Luime. (2015) Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review. The Journal of Rheumatology 42:11, pages 2012-2022.
Crossref
Bruno Fautrel & Alfons A. den Broeder. (2015) De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?. Best Practice & Research Clinical Rheumatology 29:4-5, pages 550-565.
Crossref
Stefan Siebert, Alexander Tsoukas, Jamie Robertson & Iain McInnes. (2015) Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. Pharmacological Reviews 67:2, pages 280-309.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.